Literature DB >> 17022734

Early genetic changes involved in low-grade astrocytic tumor development.

Dolores Arjona1, Juan Antonio Rey, Shirley M Taylor.   

Abstract

Astrocytomas represent the most common form of glial tumors. The most malignant grade of these tumors, glioblastoma multiforme, may arise as a malignant progression from low-grade astrocytoma through anaplastic astrocytoma to secondary GBM, or else it may arise "de novo" as primary GBM. Both types of glioblastoma are usually histologically indistinguishable. However, distinct molecular alterations have been described between them that potentially allow differentiation between the two mechanisms of origin. Since malignant transformation is a multistep process, we summarize in this review the earliest genetic changes that seem to be involved in the appearance and development of low-grade astrocytic tumors, where early detection and treatment could be possible.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17022734     DOI: 10.2174/156652406778195017

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  8 in total

1.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

2.  Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis.

Authors:  Whitney B Pope; Jenny H Chen; Jun Dong; Marc R J Carlson; Alla Perlina; Timothy F Cloughesy; Linda M Liau; Paul S Mischel; Phioanh Nghiemphu; Albert Lai; Stanley F Nelson
Journal:  Radiology       Date:  2008-10       Impact factor: 11.105

3.  Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma.

Authors:  Clemens Seidel; Nils Dörner; Matthias Osswald; Antje Wick; Michael Platten; Martin Bendszus; Wolfgang Wick
Journal:  BMC Cancer       Date:  2011-04-12       Impact factor: 4.430

Review 4.  Glioblastoma: molecular pathways, stem cells and therapeutic targets.

Authors:  Meena Jhanwar-Uniyal; Michael Labagnara; Marissa Friedman; Amanda Kwasnicki; Raj Murali
Journal:  Cancers (Basel)       Date:  2015-03-25       Impact factor: 6.639

5.  Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment.

Authors:  Amanda L Hudson; Nicole R Parker; Peter Khong; Jonathon F Parkinson; Trisha Dwight; Rowan J Ikin; Ying Zhu; Jason Chen; Helen R Wheeler; Viive M Howell
Journal:  Front Oncol       Date:  2018-08-13       Impact factor: 6.244

Review 6.  Glioblastoma multiforme: State of the art and future therapeutics.

Authors:  Taylor A Wilson; Matthias A Karajannis; David H Harter
Journal:  Surg Neurol Int       Date:  2014-05-08

Review 7.  Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas.

Authors:  Patrick-Denis St-Coeur; Mohamed Touaibia; Miroslava Cuperlovic-Culf; Pier Morin
Journal:  Genomics Proteomics Bioinformatics       Date:  2013-06-01       Impact factor: 7.691

8.  Annexin 2A sustains glioblastoma cell dissemination and proliferation.

Authors:  Francesca Maule; Silvia Bresolin; Elena Rampazzo; Daniele Boso; Alessandro Della Puppa; Giovanni Esposito; Elena Porcù; Stefania Mitola; Giuseppe Lombardi; Benedetta Accordi; Manuela Tumino; Giuseppe Basso; Luca Persano
Journal:  Oncotarget       Date:  2016-08-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.